Website News and Research

RSS

IRIS International announces the launch of new and improved corporate website

IRIS International, Inc., a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, announced today the launch of its new and improved corporate website at www.proiris.com, featuring a newly designed homepage and enhanced navigation tools with access to the latest company information.

17 Mar 2010

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.

17 Mar 2010

Unapproved drugs: National Minority Quality Forum launches new public information campaign

The National Minority Quality Forum (The Forum) is launching a new public information campaign aimed to help educate consumers, physicians, and policymakers about the risks associated with prescribing and taking unapproved drugs that have not been subjected to the rigorous Food and Drug Administration’s (FDA) review and approval process.

17 Mar 2010

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Vertex Pharmaceuticals Incorporated today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010.

17 Mar 2010

New industry ecosystem design to change effect of asthma worldwide published

Blue Spoon Consulting Group, LLC, today published its design for an industry ecosystem to change the effect of asthma worldwide. Available for download through the Blue Spoon Consulting website (www.bluespoonconsulting.com), the ecosystem makes novel linkages between industry players to create new health and economic value.

16 Mar 2010

Illumina announces enhancement to OmniExpress BeadChip

Illumina, Inc. today unveiled its new HumanOmniExpress+ Custom BeadChip (OmniExpress+), an enhancement to the recently announced OmniExpress BeadChip that allows for the addition of up to 200,000 custom variants for a total of >900k variants per sample. OmniExpress+ leverages the proven iSelect custom genotyping infrastructure to provide researchers with unlimited flexibility in adding custom content for disease or pathway-specific markers, rare variants from the 1,000 Genomes Project, or panels for fine-mapping onto the industry’s most optimal set of SNPs.

From Illumina, Inc. 16 Mar 2010

Most influential advances in cardiopulmonary imaging: High-resolution CT and CT pulmonary angiography

Advances in computed tomography providing high-resolution images of the lungs and a new approach to diagnosis of pulmonary embolism are "the most influential" changes in cardiopulmonary imaging over the past 25 years, according to a panel of experts surveyed in the February Journal of Thoracic Imaging official journal of the Society of Thoracic Radiology and the Japanese and Korean Societies of Thoracic Radiology.

16 Mar 2010

F1000 adds new Otolaryngology section to support extensive medicine coverage

Faculty of 1000 Biology, the award-winning literature awareness service for the life sciences, has launched the much anticipated Otolaryngology Faculty.

16 Mar 2010

Cardium Therapeutics closes $11.3M registered direct offering

Cardium Therapeutics, Inc. today reported it has closed its registered direct offering announced on March 9, 2010. The offering resulted in total gross proceeds to Cardium of $11.3 million, which included the full initial offering amount of $10.0 million, plus an additional overallotment amount purchased by institutional investors.

15 Mar 2010

Orexo AB summons shareholders for extraordinary general meeting

The shareholders in Orexo AB (publ) are summoned to an extraordinary general meeting to be held on Wednesday 31 March 2010, at 10.00 am at IVA’s Konferenscenter, Grev Turegatan 16, in Stockholm, Sweden.

15 Mar 2010

FDA looks into supply chain of black and red pepper as part of Salmonella Montevideo investigation

As part of the Salmonella Montevideo investigation, the Food and Drug Administration has been actively investigating the supply chain of black and red pepper supplied to Daniele International Inc., Pascoag, R.I.

15 Mar 2010

Development of promising new cancer therapies: OICR announces $1M investment

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced an investment of $1 million towards the development of two new promising cancer therapies.

12 Mar 2010

SpineUniverse introduces Community Case Discussion tool for spine professionals

SpineUniverse, a Vertical Health website, proudly introduces the Community Case Discussion for its network of spine professionals. This interactive forum allows spine specialists to engage with one another in the SpineUniverse Spinal Case Study Library.

12 Mar 2010

HTDS receives Registration Certificate for MEVAC-Vari vaccine in Guatemala

Hard to Treat Diseases and its subsidiary Mellow Hope announce that the company received Registration Certificate for its MEVAC-Vari vaccine in Guatemala.

12 Mar 2010

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended January 31, 2010. The company also provided an update on its clinical programs and corporate developments.

From Thermo Fisher Scientific Inc. 11 Mar 2010

Whole genome sequencing of entire family beneficial

The Institute for Systems Biology (ISB) has analyzed the first whole genome sequences of a human family of four. The findings of a project funded through a partnership between ISB and the University of Luxembourg was published online today by Science on its Science Express website. It demonstrates the benefit of sequencing entire families, including lowering error rates, identifying rare genetic variants and identifying disease-linked genes.

11 Mar 2010

Medela launches new website on breast feeding and insurance

Medela today announced the launch of an important new resource - www.breastfeedinginsurance.com - where new and expectant mothers can access comprehensive information and tools to help them discover if their breastfeeding related expenses, such as breastpump rental/purchase or lactation consultants, are covered by insurance.

11 Mar 2010

Harvard School of Public Health launches Firearms Research Digest database

A new firearms research database launched by the Harvard School of Public Health makes scholarly articles more accessible to reporters, law enforcement, public health officials, policymakers, and the general public.

11 Mar 2010

New changes made to the Dose Conversion Guidelines on Fentanyl Transdermal Systems

The manufacturers of Fentanyl Transdermal Systems, in collaboration with Health Canada, would like to inform Canadians of important new changes made to the Dose Conversion Guidelines in the Product Monograph. These guidelines are used to help determine what dosage of Fentanyl Transdermal Systems is appropriate for each individual patient.

11 Mar 2010

Study supports Myriad Genetics' PROLARIS molecular diagnostic test for predicting prostate cancer recurrence

Myriad Genetics, Inc. today said data that provides further clinical validation supporting its newest molecular diagnostic product, PROLARIS™, was recently presented at the 2010 Genitourinary Cancers Symposium in San Francisco. The abstract of the presentation entitled: "Cell Cycle Genes Predict Recurrence After Radical Prostatectomy" by Gregory P. Swanson, M.D., University of Texas Health Science Center San Antonio, and colleagues is now available on the American Society of Clinical Oncology's website, www.asco.org.

11 Mar 2010